Programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) are co-inhibitory ICPs; they are expressed on activated tumor-specific CD4+ cells and CD8+ T-lymphocytes, and inhibit the progression of the immune reaction. Here, CD8A is linked to neoplasm.